View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
Request paper copies of the proxy materials by clicking the "online" or "email" buttons below, or by phone by dialing 866-648-8133.
Your vote is Important!
Please vote your proxy online now or by phone by
dialing 866-892-1702.
You must register to be eligible to participate in the meeting.
Date: March 11, 2026
Time: 5:00 PM ET
Register By: March 10, 2026 at 5:00 PM ET
Enanta is a clinical stage biotechnology company dedicated to creating oral drugs for serious viral infections and immunological diseases. Our story began in 1995. Through the years we have collaborated with AbbVie to discover two protease inhibitor compounds that were each developed and commercialized as part of an AbbVie combination regimen for chronic hepatitis C virus infection (glecparevir in MAVYRET® and paritaprevir in VIEKIRA PAK®. Currently, our clinical programs are focused on the treatment of respiratory syncytial virus, and research and development programs are targeting key drivers of the type 2 immune response with KIT, STAT6 and MRGPRX2 inhibition.